Anti-myostatin antibody emugrobart fails in muscle wasting diseases, raising fresh questions about the GLP-1 muscle loss problem
Read More
Imitex today announced the appointment of Dr. James Campbell as Chief Executive Officer, effective immediately.
Read More
Pfizer completed its acquisition of Metsera for approximately US$10 billion, following a bidding war with Novo Nordisk.
Read More
AstraZeneca today completed its acquisition of SixPeaks Bio for up to US$300 million, adding a preclinical muscle-preservation biologic to its obesity franchise.
Read More
Imitex presented at the Early Stage Innovation Forum (ESIF) during the AusBiotech International Conference in Melbourne, one of the Asia-Pacific region's leading gatherings of biotechnology investors and industry leaders.
Read More
Imitex today announced the successful close of its seed funding round, raising capital to develop a proprietary AI-based drug discovery platform in partnership with Singapore-based QDX Technologies.
Read More
Landmark NIH Study Confirms MEF2 as a Master Regulator of Exercise Response
Read More
Eli Lilly today announced its acquisition of Versanis Bio for up to US$1.9 billion, adding bimagrumab — a myostatin inhibitor being tested as a combination therapy with GLP-1 drugs — to its obesity portfolio.
Read More